Systematical evaluation of the effects of sample collection procedures on low‐molecular‐weight serum/plasma proteome profiling

Blood is an ideal source for biomarker discovery. However, little has been done to address the effects of sampling, handling and storage procedures on serum/plasma proteomes. We used magnetic bead‐based MALDI‐TOF MS to systematically evaluate the influence of each procedure on low‐molecular‐weight serum/plasma proteome profiling on the basis of the whole spectra. We found that sampling procedures, including the selection of blood collection tubes and anticoagulants, variations in clotting time or time lag before centrifugation, and hemolysis, displayed significant effects on the proteomes. Moreover, serum and plasma were mutually incompatible for proteome comparison. By contrast, overnight fasting, handling procedures, including centrifugation speeds (1500×g vs. 3000×g) or time (15 min vs. 30 min), and storage conditions, such as at 4°C or 25°C for up to 24 h or at −80°C for up to 3 months, and repeated freeze/thaw of up to ten cycles, had relatively minor effects on the proteomes based upon our analysis of about 100 peaks. We concluded that low‐molecular‐weight serum/plasma proteomes were diversely affected by sampling, handling and storage with most change from variations of sampling procedures. We therefore suggest the necessity of standardizing sampling procedure for proteome comparison and biomarker discovery.

[1]  Rob Pieters,et al.  Identification of Tumor‐Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors , 2003, Journal of neuropathology and experimental neurology.

[2]  S. Hanash Disease proteomics : Proteomics , 2003 .

[3]  I. Jacobs,et al.  Screening for ovarian cancer , 1999, The Lancet.

[4]  J. White EDTA-induced changes in platelet structure and function: clot retraction , 2000, Platelets.

[5]  Hongyu Zhao,et al.  Serum protein markers for early detection of ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Graham B. I. Scott,et al.  HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples , 2005, Proteomics.

[7]  M. Kostrzewa,et al.  Mass spectrometry-based clinical proteomics. , 2003, Pharmacogenomics.

[8]  Michael J Campa,et al.  Identification and validation of a potential lung cancer serum biomarker detected by matrix‐assisted laser desorption/ionization‐time of flight spectra analysis , 2003, Proteomics.

[9]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[10]  Ralf Ketterlinus,et al.  Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. , 2005, BioTechniques.

[11]  Weimin Zhu,et al.  Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. , 2003, Journal of proteome research.

[12]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[13]  T. Yip,et al.  Synthetic metal-binding protein surface domains for metal ion-dependent interaction chromatography. I. Analysis of bound metal ions by matrix-assisted UV laser desorption time-of-flight mass spectrometry. , 1992, Journal of chromatography.

[14]  Fang Wang,et al.  The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two‐dimensional electrophoresis gels and identification of 325 distinct proteins , 2003, Proteomics.

[15]  S. Baumann,et al.  Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2005, Clinical chemistry.

[16]  D. Chan,et al.  Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.

[17]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[18]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[19]  Ronald J. Moore,et al.  Toward a Human Blood Serum Proteome , 2002, Molecular & Cellular Proteomics.

[20]  P. Ludbrook,et al.  Sustained Fibrinolysis After Administration of t-PA Despite Its Short Half-Life in the Circulation , 1987, Thrombosis and Haemostasis.

[21]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[22]  J. Barrett,et al.  Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. , 2005, Clinical chemistry.

[23]  K. Spencer The influence of different sample collection types on the levels of markers used for Down's syndrome screening as measured by the Kryptor Immunosassay system , 2003, Annals of clinical biochemistry.

[24]  D. Hochstrasser,et al.  A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt‐Jakob disease , 2003, Proteomics.

[25]  E. Petricoin,et al.  SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. , 2004, Current opinion in biotechnology.

[26]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[27]  E. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[28]  Douglas C Pearl,et al.  Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.